MR1 presents vitamin B6–related compounds for recognition by MR1-reactive T cells
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2414792121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Mitchell P McInerney und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Austral…. Hauptthemen laut MEDLINE: Minor Histocompatibility Antigens, Histocompatibility Antigens Class I, Vitamin B 6, Pyridoxal Phosphate. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Department of Education and Training | Australian Research Council (ARC), DHAC | National Health and Medical Research Council (NHMRC), HHS | National Institutes of Health (NIH).
Abstract (Originalsprache)
The major histocompatibility complex class I related protein (MR1) presents microbially derived vitamin B2 precursors to mucosal-associated invariant T (MAIT) cells. MR1 can also present other metabolites to activate MR1-restricted T cells expressing more diverse T cell receptors (TCRs), some with anti-tumor reactivity. However, knowledge of the range of the antigen(s) that can activate diverse MR1-reactive T cells remains incomplete. Here, we identify pyridoxal (vitamin B6) as a naturally presented MR1 ligand using unbiased mass spectrometry analyses of MR1-bound metabolites. Pyridoxal, and the related compound, pyridoxal 5-phosphate bound to MR1 and enabled cell surface upregulation of wild type MR1*01 and MR1 expressing the Arg9His polymorphism associated with the MR1*04 allotype in a manner dependent on Lys43-mediated Schiff-base formation. Crystal structures of MR1*01 in complex with pyridoxal and pyridoxal 5-phosphate showed how these ligands were accommodated within the A-pocket of MR1. T cell lines transduced with the 7.G5 TCR, which has reported “pan-cancer” specificity, were specifically activated by pyridoxal presented by antigen-presenting cells expressing MR1*01 and MR1 allotypes bearing the less common Arg9His polymorphism. 7.G5 T cells also recognized, to a lesser extent, pyridoxal 5-phosphate and, importantly, recognition of both vitamers was blocked by an anti-MR1 antibody. 7.G5 TCR reactivity toward pyridoxal was enhanced when presented by the Arg9His polymorphism-bearing MR1 allotypes. Vitamin B6, and vitamers thereof, have been associated with various cancers, and here we describe a link between this ligand, MR1, and its allomorphs, and the pan-cancer 7.G5 TCR. This work identifies an MR1 ligand that can activate a diverse MR1-restricted TCR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
- Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, VIC 3052, Australia.
- Centre for Chemistry and Drug Discovery and Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD 40…
- Mass Spectrometry and Proteomics Facility, Bio21 Institute, The University of Melbourne, Parkville, VIC 3052, Australia.
- Institute of Infection and Immunity, Cardiff University, School of Medicine, Heath Park, Cardiff CF10 3AT, United Kingdom.
ORCID-Profile: Mitchell P McInerney, Wael Awad, Michael N T Souter, Mohamed R Abdelaal, Chloe M Shepherd, Lucy J Meehan, Jeffrey Y W Mak, Zhenjun Chen, Ching-Seng Ang, David P Fairlie, Jérôme Le Nours, Patricia T Illing, Jamie Rossjohn, Anthony W Purcell
Förderung
- Department of Education and Training | Australian Research Council (ARC)
- DHAC | National Health and Medical Research Council (NHMRC)
- HHS | National Institutes of Health (NIH)
- NIAID NIH HHS
Zitieren
APA
McInerney, M. P., Awad, W., Souter, M. N. T., Kang, Y., Wang, C. J. H., Chan Yew Poa, K., Abdelaal, M. R., Le, N. H., Shepherd, C. M., McNeice, C., Meehan, L. J., Nelson, A. G., Raynes, J. M., Mak, J. Y. W., McCluskey, J., Chen, Z., Ang, C. S., Fairlie, D. P., Le Nours, J., …, & Purcell, A. W. (2024). MR1 presents vitamin B6–related compounds for recognition by MR1-reactive T cells. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2414792121
Vancouver
McInerney MP, Awad W, Souter MNT, Kang Y, Wang CJH, Chan Yew Poa K, et al. MR1 presents vitamin B6–related compounds for recognition by MR1-reactive T cells. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2414792121
BibTeX
@article{McInerney2024,
author = {McInerney, Mitchell P and Awad, Wael and Souter, Michael N T and Kang, Yang and Wang, Carl J H and Chan Yew Poa, Kean and Abdelaal, Mohamed R and Le, Ngoc H and Shepherd, Chloe M and McNeice, Conor and Meehan, Lucy J and Nelson, Adam G and Raynes, Jeremy M and Mak, Jeffrey Y W and McCluskey, James and Chen, Zhenjun and Ang, Ching-Seng and Fairlie, David P and Le Nours, Jérôme and Illing, Patricia T and Rossjohn, Jamie and Purcell, Anthony W},
title = {MR1 presents vitamin B6–related compounds for recognition by MR1-reactive T cells},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2414792121}
}
EUVIMED